Use of a Novel Diet (UC Diet) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ulcerative Colitis
- Sponsor
- Children's Hospital of Philadelphia
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Clinical Remission
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Ulcerative colitis is a chronic inflammatory disease primarily involving the colon and has long been considered to be due to a dysregulated immune response targeting the colon, and involves unknown environmental factors. Currently, no effective therapy targets the microbiota or its interaction with the colonic epithelium. Diet has a significant impact on the composition of the microbiota; however, no dietary intervention to date has proven effective for induction of remission. The primary objective of this study is to determine whether the Ulcerative Colitis Diet (UCD) can induce remission or response in pediatric UC patients with active mild to moderate UC on a stable medication.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Informed consent
- •Established diagnosis of UC
- •Age: 8-19 (inclusive)
- •Mild to moderate active disease, 10\<PUCAI\<45
- •Stable medication (IMM/5ASA) use or no medication use for the past 6 weeks.
- •Participant has agreed to follow the UCD for 12 weeks
Exclusion Criteria
- •Any proven current infection such as positive stool culture, parasite or C. difficile within the past 4 weeks
- •Antibiotic or corticosteroid use in the past 2 weeks
- •Use of biologics in present or in the past
- •PUCAI\>45
- •Acute severe UC in the previous 12 months
- •Current extra intestinal manifestation of UC
- •Primary Sclerosing Cholangitis (PSC) or liver disease
- •Pregnancy
- •Known food allergy to mandatory foods in the UCD
Outcomes
Primary Outcomes
Clinical Remission
Time Frame: At 6 weeks following enrollment
Remission defined by the Pediatric Ulcerative Colitis Activity Index (PUCAI)
Secondary Outcomes
- Change in C-reactive protein (CRP) between baseline and week 12(12 weeks)
- Change in fecal calprotectin (FCP) between baseline and week 12(12 weeks)
- Dietary Compliance(Up to 12 weeks following enrollment)
- Change in erythrocyte sedimentation rate (ESR) between baseline and week 12(12 weeks)
- Microbial composition of the gastrointestinal tract(12 weeks)